{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:52:30Z","timestamp":1788317550130,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T00:00:00Z","timestamp":1656115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T00:00:00Z","timestamp":1656115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurocrit Care"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Aneurysmal subarachnoid hemorrhage (aSAH) is an important indication for intensive care unit admission and may lead to significant morbidity and mortality. We assessed the ability of C-terminal proarginine vasopressin (CT-proAVP) to predict disease outcome, mortality, and delayed cerebral ischemia (DCI) in critically ill patients with aSAH compared with the World Federation of Neurological Surgeons (WFNS) score and Acute Physiological and Chronic Health Evaluation IV (APACHE IV) model.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>C-terminal proarginine vasopressin was collected on admission in this single-center, prospective, observational cohort study. The primary aim was to investigate the relationship between CT-proAVP and poor functional outcome at 1\u00a0year (Glasgow Outcome Scale score 1\u20133) in a multivariable logistic regression model adjusted for WFNS and APACHE IV scores. Secondary aims were mortality and DCI. The multivariable logistic regression model for DCI was also adjusted for the modified Fisher scale.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In 100 patients, the median CT-proAVP level was 24.9\u00a0pmol\/L (interquartile range 11.5\u201353.8); 45 patients had a poor 1-year functional outcome, 19 patients died within 30\u00a0days, 25 patients died within 1\u00a0year, and DCI occurred in 28 patients. Receiver operating characteristics curves revealed high accuracy for CT-proAVP to identify patients with poor 1-year functional outcome (area under the curve [AUC] 0.84, 95% confidence interval [CI] 0.77\u20130.92, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), 30-day mortality (AUC 0.84, 95% CI 0.76\u20130.93, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), and 1-year mortality (AUC 0.79, 95% CI 0.69\u20130.89, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). CT-proAVP had a low AUC for identifying patients with DCI (AUC 0.67, 95% CI 0.55\u20130.79, <jats:italic>p<\/jats:italic> 0.008). CT-proAVP\u2009\u2265\u200924.9 pmo\/L proved to be a significant predictor for poor 1-year functional outcome (odds ratio [OR] 8.04, 95% CI 2.97\u201321.75, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), and CT-proAVP\u2009\u2265\u200929.1\u00a0pmol\/L and\u2009\u2265\u200927.7\u00a0pmol\/L were significant predictors for 30-day and 1-year mortality (OR 9.31, 95% CI 1.55\u201356.07, <jats:italic>p<\/jats:italic> 0.015 and OR 5.15, 95% CI 1.48\u201317.93, <jats:italic>p<\/jats:italic> 0.010) in multivariable models with WFNS and APACHE IV scores. CT-proAVP\u2009\u2265\u200929.5\u00a0pmol\/L was not a significant predictor for DCI in a multivariable model adjusted for the modified Fisher scale (<jats:italic>p<\/jats:italic>\u2009=\u20090.061).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>C-terminal proarginine vasopressin was able to predict poor functional outcome and mortality in critically ill patients with aSAH. Its prognostic ability to predict DCI was low.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial Registration<\/jats:title>\n                <jats:p>Nederlands Trial Register: NTR4118.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12028-022-01540-0","type":"journal-article","created":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T00:02:33Z","timestamp":1656115353000},"page":"678-688","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["C-Terminal Proarginine Vasopressin is Associated with Disease Outcome and Mortality, but not with Delayed Cerebral Ischemia in Critically Ill Patients with an Aneurysmal Subarachnoid Hemorrhage: A Prospective Cohort Study"],"prefix":"10.1007","volume":"37","clinical-trial-number":[{"clinical-trial-number":"ntr4118","registry":"10.18810\/dutch-trial-register"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8666-9810","authenticated-orcid":false,"given":"Jos A. H.","family":"van Oers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dharmanand","family":"Ramnarain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemarie","family":"Oldenbeuving","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piet","family":"Vos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerwin","family":"Roks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvette","family":"Kluiters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albertus","family":"Beishuizen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan W.","family":"de Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harm-Jan","family":"de Grooth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armand R. J.","family":"Girbes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,25]]},"reference":[{"key":"1540_CR1","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/S0140-6736(07)60153-6","volume":"369","author":"J Van Gijn","year":"2007","unstructured":"Van Gijn J, Kerr RS, Rinkel GJE. Subarachnoid haemorrhage. Lancet. 2007;369:306\u201318.","journal-title":"Lancet"},{"key":"1540_CR2","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1161\/01.STR.13.5.629","volume":"13","author":"B Herman","year":"1982","unstructured":"Herman B, Leyten AC, van Luijk JH, et al. Epidemiology of stroke in Tilburg, the Netherlands. The population-based stroke incidence register: 2. Incidence, initial clinical picture and medical care, and three-week case fatality. Stroke. 1982;13:629\u201334.","journal-title":"Stroke"},{"key":"1540_CR3","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1136\/jnnp.68.3.337","volume":"68","author":"YB Roos","year":"2000","unstructured":"Roos YB, de Haan RJ, Beenen LF, et al. Complications and outcome in patients with aneurysmal subarachnoid haemorrhage: a prospective hospital based cohort study in the Netherlands. J Neurol Neurosurg Psychiatry. 2000;68:337\u201341.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1540_CR4","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/S1474-4422(11)70017-5","volume":"10","author":"GJ Rinkel","year":"2011","unstructured":"Rinkel GJ, Algra A. Long-term outcomes of patients with aneurysmal subarachnoid haemorrhage. Lancet Neurol. 2011;10:349\u201356.","journal-title":"Lancet Neurol"},{"key":"1540_CR5","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S1474-4422(09)70126-7","volume":"8","author":"DJ Nieuwkamp","year":"2009","unstructured":"Nieuwkamp DJ, Setz LE, Algra A, et al. Changes in case fatality of aneurysmal subarachnoid heamorrhage over time, according to age, sex, and region: a meta-analysis. Lancet Neurol. 2009;8:635\u201342.","journal-title":"Lancet Neurol"},{"key":"1540_CR6","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1212\/WNL.0b013e3181dd42b3","volume":"74","author":"CE Lovelock","year":"2010","unstructured":"Lovelock CE, Rinkel GJE, Rothwell PM. Time trends in outcome of subarachnoid hemorrhage: population-based study and systematic review. Neurology. 2010;74:1994\u20132501.","journal-title":"Neurology"},{"key":"1540_CR7","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S1474-4422(09)70025-0","volume":"8","author":"VL Feigin","year":"2009","unstructured":"Feigin VL, Lawes C, Bennett DA, Barker-Collo SL, Parag V. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurol. 2009;8:355\u201369.","journal-title":"Lancet Neurol"},{"key":"1540_CR8","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1227\/NEU.0000000000001042","volume":"78","author":"Z Taufique","year":"2016","unstructured":"Taufique Z, May T, Meyers E, et al. Predictors of poor quality of life 1 year after subarachnoid hemorrhage. Neurosurgery. 2016;78:256\u201364.","journal-title":"Neurosurgery"},{"key":"1540_CR9","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1161\/01.STR.16.4.562","volume":"16","author":"NF Kassell","year":"1985","unstructured":"Kassell NF, Sasaki T, Colohan ART, Nazar G. Cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Stroke. 1985;16:562\u201372.","journal-title":"Stroke"},{"key":"1540_CR10","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1161\/STROKEAHA.108.544700","volume":"40","author":"JA Frontera","year":"2009","unstructured":"Frontera JA, Fernandez A, Schmidt M, et al. Defining Vasospasm after subarachnoid hemorrhage: What is the most clinically relevant definition? Stroke. 2009;40:1963\u20138.","journal-title":"Stroke"},{"key":"1540_CR11","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1161\/STROKEAHA.110.589275","volume":"41","author":"MDI Vergouwen","year":"2010","unstructured":"Vergouwen MDI, Vermeulen M, van Gijn J, et al. Definition of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational studies: proposal of a multidisciplinary research group. Stroke. 2010;41:2391\u20135.","journal-title":"Stroke"},{"key":"1540_CR12","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/cc5958","volume":"11","author":"SG Keyrouz","year":"2007","unstructured":"Keyrouz SG, Diringer MN. Clinical review: prevention and therapy of vasospasm in subarachnoid hemorrhage. Crit Care. 2007;11:220.","journal-title":"Crit Care"},{"key":"1540_CR13","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1385\/NCC:2:2:110","volume":"2","author":"DS Rosen","year":"2005","unstructured":"Rosen DS, Macdonald RL. Subarachnoid hemorrhage grading scales: a systematic review. Neurocrit Care. 2005;2:110\u20138.","journal-title":"Neurocrit Care"},{"key":"1540_CR14","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/cc8204","volume":"14","author":"JL Vincent","year":"2010","unstructured":"Vincent JL, Moreno R. Clinical review: scoring systems in the critically ill. Crit Care. 2010;14:207. https:\/\/doi.org\/10.1186\/cc8204.","journal-title":"Crit Care"},{"key":"1540_CR15","first-page":"21","volume":"59","author":"JA Frontera","year":"2006","unstructured":"Frontera JA, Claasen J, Schmidt JM, et al. Prediction of symptomatic vasospasm after subarachnoid hemorrhage: the modified Fischer scale. Neurosurgery. 2006;59:21\u20137.","journal-title":"Neurosurgery"},{"key":"1540_CR16","first-page":"13101","volume":"140","author":"M Katan","year":"2010","unstructured":"Katan M, Christ-Crain M. The stress hormone copeptin: a new prognostic biomarker in acute illness. Swiss Med Wkly. 2010;140:13101.","journal-title":"Swiss Med Wkly"},{"key":"1540_CR17","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1373\/clinchem.2005.060038","volume":"52","author":"NG Morgenthaler","year":"2006","unstructured":"Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem. 2006;52:112\u20139.","journal-title":"Clin Chem"},{"key":"1540_CR18","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/978-3-211-98811-4_41","volume":"106","author":"A Kleindienst","year":"2010","unstructured":"Kleindienst A, Brabant G, Morgenthaler NG, et al. Following brain trauma, copeptin, a stable peptide derived from the AVP precursor, does not reflect osmoregulation but correlates with injury severity. Acta Neurochir Suppl. 2010;106:221\u20134.","journal-title":"Acta Neurochir Suppl"},{"key":"1540_CR19","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1471-2377-10-34","volume":"10","author":"C Zweifel","year":"2010","unstructured":"Zweifel C, Katan M, Schuetz P, et al. Copeptin is associated with mortality and outcome in patients with acute intracerebral hemorrhage. BMC Neurol. 2010;10:34.","journal-title":"BMC Neurol"},{"key":"1540_CR20","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1002\/ana.21783","volume":"66","author":"M Katan","year":"2010","unstructured":"Katan M, Fluri F, Morgenthaler NG, et al. Copeptin: a novel, independent prognostic marker in patients with ischemic stroke. Ann Neurol. 2010;66:799\u2013808.","journal-title":"Ann Neurol"},{"key":"1540_CR21","doi-asserted-by":"publisher","first-page":"R288","DOI":"10.1186\/cc10575","volume":"15","author":"XD Zhu","year":"2011","unstructured":"Zhu XD, Chen JS, Zhou F, et al. Detection of copeptin in peripheral blood of patients with aneurysmal subarachnoid hemorrhage. Crit Care. 2011;15:R288.","journal-title":"Crit Care"},{"key":"1540_CR22","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.cca.2017.10.009","volume":"475","author":"YK Zheng","year":"2017","unstructured":"Zheng YK, Dong XQ, Du Q, et al. Comparison of plasma copeptin and multiple biomarkers for assessing prognosis of patients with aneurysmal subarachnoid hemorrhage. Clin Chim Acta. 2017;475:64\u20139.","journal-title":"Clin Chim Acta"},{"key":"1540_CR23","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jneuroim.2019.03.007","volume":"330","author":"Z Zuo","year":"2019","unstructured":"Zuo Z, Ji X. Prognostic value of copeptin in patients with aneurysmal subarachnoid hemorrhage. J Neuroimmunol. 2019;330:116\u201322.","journal-title":"J Neuroimmunol"},{"key":"1540_CR24","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S1474-4422(09)70126-7","volume":"8","author":"DJ Nieuwkamp","year":"2009","unstructured":"Nieuwkamp DJ, Setz LE, Algra A, et al. Changes in case fatality of aneurysmal subarachnoid haemorrhage over time, according to age, sex, and region: a meta-analysis. Lancet Neurol. 2009;8:635\u201342.","journal-title":"Lancet Neurol"},{"key":"1540_CR25","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1001\/jamaneurol.2019.0006","volume":"76","author":"N Etminan","year":"2019","unstructured":"Etminan N, Chang HS, Hackenberg K, et al. Worldwide incidence of aneurysmal subarachnoid hemorrhage according to region, time period, blood pressure, and smoking prevalence in the population: a systematic review and meta-analysis. JAMA Neurol. 2019;76:588\u201397.","journal-title":"JAMA Neurol"},{"key":"1540_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040296","volume":"4","author":"E Von Elm","year":"2007","unstructured":"Von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007;4: e296.","journal-title":"PLoS Med"},{"key":"1540_CR27","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/S0140-6736(75)92830-5","volume":"1","author":"B Jennet","year":"1975","unstructured":"Jennet B, Bond M. Assessment of outcome after severe brain damage. Lancet. 1975;1:480\u20134.","journal-title":"Lancet"},{"key":"1540_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0053191","volume":"8","author":"C Fung","year":"2013","unstructured":"Fung C, De Marchis GM, Katan M, et al. Copeptin as a marker for severity and prognosis of aneurysmal subarachnoid hemorrhage. PLoS ONE. 2013;8: e53191.","journal-title":"PLoS ONE"},{"key":"1540_CR29","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/cc10594","volume":"16","author":"RJ Tamargo","year":"2012","unstructured":"Tamargo RJ. Copeptin in aneurysmal subarachnoid hemorrhage. Crit Care. 2012;16:103.","journal-title":"Crit Care"},{"key":"1540_CR30","doi-asserted-by":"publisher","first-page":"274","DOI":"10.3390\/life11040274","volume":"11","author":"JK Rhim","year":"2021","unstructured":"Rhim JK, Youn DH, Kim BJ, et al. The role of consecutive plasma copeptin levels in the screening of delayed cerebral ischemia in poor grade subarachnoid hemorrhage. Life. 2021;11:274.","journal-title":"Life"},{"key":"1540_CR31","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.3171\/2017.10.JNS17795","volume":"130","author":"SJ Fernandez","year":"2019","unstructured":"Fernandez SJ, Barakat I, Ziogas J, et al. Association of copeptin, a surrogate marker of arginine vasopressin, with cerebral vasospasm and delayed ischemic neurologic deficit after aneurysmal subarachnoid hemorrhage. J Neurosurg. 2019;130:1446\u201352.","journal-title":"J Neurosurg"},{"key":"1540_CR32","doi-asserted-by":"publisher","first-page":"266","DOI":"10.3171\/jns.1988.68.2.0266","volume":"68","author":"TJ Delgado","year":"1988","unstructured":"Delgado TJ, Arbab MA, Warberg J, Svendgaard NA. The role of vasopressin in acute cerebral vasospasm. Effect on spasm of a vasopressin antagonist or vasopressin antiserum. J Neurosurg. 1988;68:266\u201373.","journal-title":"J Neurosurg"},{"key":"1540_CR33","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1161\/01.STR.0000039405.31526.06","volume":"33","author":"A Shuaib","year":"2002","unstructured":"Shuaib A, Wang CX, Yang T, Noor R. Effects of nonpeptide V(1) vasopressin receptor antagonist SR-49059 on infarction volume and recovery of function in a focal embolic stroke model. Stroke. 2002;33:3033\u20137.","journal-title":"Stroke"},{"key":"1540_CR34","doi-asserted-by":"publisher","first-page":"3114","DOI":"10.1097\/CCM.0b013e3181bc7bd5","volume":"37","author":"R Bellomo","year":"2009","unstructured":"Bellomo R, Warrillow SJ, Reade MC. Why we should be aware of single-center trials. Crit Care Med. 2009;37:3114\u20139.","journal-title":"Crit Care Med"}],"container-title":["Neurocritical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12028-022-01540-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12028-022-01540-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12028-022-01540-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T21:31:50Z","timestamp":1668720710000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12028-022-01540-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,25]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1540"],"URL":"https:\/\/doi.org\/10.1007\/s12028-022-01540-0","relation":{},"ISSN":["1541-6933","1556-0961"],"issn-type":[{"value":"1541-6933","type":"print"},{"value":"1556-0961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,25]]},"assertion":[{"value":"18 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No financial or nonfinancial competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The study protocol was approved by the Medisch Ethische Toetsingscommissie Brabant (Tilburg, Netherlands) (NL-number: NL45096.008.13). All patients agreed by informed consent that a blood sample could be collected to measure CT-proAVP levels.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval\/informed consent"}}]}}